Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 187

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Advances in the Development of Anti-Toxoplasma gondii Vaccines: Challenges, Opportunities, and Perspectives

Open access
Wang, Jin-Lei, Zhang, Nian-Zhang, Li, Ting-Ting, He, Jun-Jun, Elsheikha, Hany M., Zhu, Xing-Quan · 2019 · Trends in Parasitology

Abstract

Important progress has been made in understanding how immunity is elicited against Toxoplasma gondii - a complex pathogen with multiple mechanisms of immune evasion. Many vaccine candidates have been tested using various strategies in animal models. However, none of these strategies has delivered as yet, and important challenges remain in the development of vaccines that can eliminate the tissue cysts and/or fully block vertical transmission. In this review, we provide an overview of the current understanding of the host immune response to T. gondii infection and summarize the key limitations for the development of an effective, safe, and durable toxoplasmosis vaccine. We also discuss how the successes and failures in developing and testing vaccine candidates have provided a roadmap for future vaccine development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pt.2019.01.005

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 82

  1. Montoya, 2004, Toxoplasmosis, Lancet, 363, 1965, 10.1016/S0140-6736(04)16412-X · DOI · Paper page
  2. Robert-Gangneux, 2012, Epidemiology of and diagnostic strategies for toxoplasmosis, Clin. Microbiol. Rev., 25, 264, 10.1128/CMR.05013-11 · DOI · Paper page
  3. Elsheikha, 2008, Congenital toxoplasmosis: priorities for further health promotion action, Public Health, 122, 335, 10.1016/j.puhe.2007.08.009 · DOI · Paper page
  4. Wang, 2017, Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis, Lancet HIV, 4, e177, 10.1016/S2352-3018(17)30005-X · DOI · Paper page
  5. Dunay, 2018, Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice, Clin. Microbiol. Rev., 31, 10.1128/CMR.00057-17 · DOI · Paper page
  6. Buxton, 1995, A commercial vaccine for ovine toxoplasmosis, Parasitology, 110, S11, 10.1017/S003118200000144X · DOI · Paper page
  7. Yarovinsky, 2014, Innate immunity to Toxoplasma gondii infection, Nat. Rev. Immunol., 14, 109, 10.1038/nri3598 · DOI · Paper page
  8. Pittman, 2015, Long-term relationships: the complicated interplay between the host and the developmental stages of Toxoplasma gondii during acute and chronic infections, Microbiol. Mol. Biol. Rev., 79, 387, 10.1128/MMBR.00027-15 · DOI
  9. Hunter, 2012, Modulation of innate immunity by Toxoplasma gondii virulence effectors, Nat. Rev. Microbiol., 10, 766, 10.1038/nrmicro2858 · DOI · Paper page
  10. Sayles, 2000, B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii, Infect. Immun., 68, 1026, 10.1128/IAI.68.3.1026-1033.2000 · DOI · Paper page
  11. Gigley, 2009, Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain, Infect. Immun., 77, 5380, 10.1128/IAI.00649-09 · DOI
  12. Hwang, 2015, CD8+ T cell immunity in an encephalitis model of Toxoplasma gondii infection, Semin. Immunopathol., 37, 271, 10.1007/s00281-015-0483-7 · DOI
  13. Dard, 2016, Relevance of and new developments in serology for toxoplasmosis, Trends Parasitol., 32, 492, 10.1016/j.pt.2016.04.001 · doi:10.1016/j.pt.2016.04.001
  14. Li, 2018, Moving towards improved vaccines for Toxoplasma gondii, Expert Opin. Biol. Ther., 18, 273, 10.1080/14712598.2018.1413086 · DOI
  15. Zhang, 2015, Recent advances in developing vaccines against Toxoplasma gondii: an update, Expert Rev. Vaccines, 14, 1609, 10.1586/14760584.2015.1098539 · DOI
  16. Hiszczyńska-Sawicka, 2014, Veterinary vaccines against toxoplasmosis, Parasitology, 141, 1365, 10.1017/S0031182014000481 · DOI
  17. Li, 2014, Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice, Vaccine, 32, 3058, 10.1016/j.vaccine.2014.03.042 · DOI
  18. Wang, 2018, Protective immune response against Toxoplasma gondii elicited by a novel yeast-based vaccine with microneme protein 16, Vaccine, 36, 3943, 10.1016/j.vaccine.2018.05.072 · DOI
  19. Lee, 2018, Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection, Vaccine, 36, 5692, 10.1016/j.vaccine.2018.08.016 · DOI
  20. Machado, 2010, Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity, Vaccine, 28, 3247, 10.1016/j.vaccine.2010.02.003 · DOI
  21. Buxton, 1991, Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant, Vet. Rec., 129, 89, 10.1136/vr.129.5.89 · DOI · Paper page
  22. Wang, 2016, The past, present, and future of genetic manipulation in Toxoplasma gondii, Trends Parasitol., 32, 542, 10.1016/j.pt.2016.04.013 · DOI
  23. Sloves, 2015, Apical organelle secretion by Toxoplasma controls innate and adaptive immunity and mediates long-term protection, J. Infect. Dis., 212, 1449, 10.1093/infdis/jiv250 · doi:10.1093/infdis/jiv250
  24. Kim, 2005, Stage-specific expression of surface antigens by Toxoplasma gondii as a mechanism to facilitate parasite persistence, J. Immunol., 174, 8038, 10.4049/jimmunol.174.12.8038 · DOI
  25. Fang, 2016, Nanoparticle-based modulation of the immune system, Annu. Rev. Chem. Biomol. Eng., 7, 305, 10.1146/annurev-chembioeng-080615-034446 · DOI
  26. Mintern, 2013, Targeting dendritic cells: the role of specific receptors in the internalization of polymer capsules, Adv. Healthc. Mater., 2, 940, 10.1002/adhm.201200441 · doi:10.1002/adhm.201200441
  27. Skwarczynski, 2010, Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system, Angew. Chem. Int. Ed. Engl., 49, 5742, 10.1002/anie.201002221 · DOI · Paper page
  28. Dacoba, 2017, Modulating the immune system through nanotechnology, Semin. Immunol., 34, 78, 10.1016/j.smim.2017.09.007 · DOI
  29. Assolini, 2017, Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications, Parasitol. Res., 116, 1603, 10.1007/s00436-017-5458-2 · DOI
  30. Rahimi, 2017, Immunological evaluation of a DNA cocktail vaccine with co-delivery of calcium phosphate nanoparticles (CaPNs) against the Toxoplasma gondii RH strain in BALB/c mice, Parasitol. Res., 116, 609, 10.1007/s00436-016-5325-6 · DOI
  31. Théry, 2002, Exosomes: composition, biogenesis and function, Nat. Rev. Immunol., 2, 569, 10.1038/nri855 · DOI · Paper page
  32. Coakley, 2015, Exosomes and other extracellular vesicles: the new communicators in parasite infections, Trends Parasitol., 31, 477, 10.1016/j.pt.2015.06.009 · DOI · Paper page
  33. Beauvillain, 2009, Exosomes are an effective vaccine against congenital toxoplasmosis in mice, Vaccine, 27, 1750, 10.1016/j.vaccine.2009.01.022 · DOI
  34. Li, 2018, Characterization of exosomes derived from Toxoplasma gondii and their functions in modulating immune responses, Int. J. Nanomed., 13, 467, 10.2147/IJN.S151110 · DOI
  35. Astronomo, 2010, Carbohydrate vaccines: developing sweet solutions to sticky situations?, Nat. Rev. Drug. Discov., 9, 308, 10.1038/nrd3012 · DOI · Paper page
  36. Rodrigues, 2015, Parasite glycobiology: a bittersweet symphony, PLoS Pathog., 11, 10.1371/journal.ppat.1005169 · DOI
  37. Jaurigue, 2017, Parasite carbohydrate vaccines, Front. Cell. Infect. Microbiol., 7, 248, 10.3389/fcimb.2017.00248 · DOI
  38. Debierre-Grockiego, 2007, Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii, J. Immunol., 179, 1129, 10.4049/jimmunol.179.2.1129 · DOI · Paper page
  39. Götze, 2015, Investigation of the protective properties of glycosylphosphatidylinositol-based vaccine candidates in a Toxoplasma gondii mouse challenge model, Glycobiology, 25, 984, 10.1093/glycob/cwv040 · DOI
  40. Howe, 1995, Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease, J. Infect. Dis., 172, 1561, 10.1093/infdis/172.6.1561 · DOI · Paper page
  41. Khan, 2007, Recent transcontinental sweep of Toxoplasma gondii driven by a single monomorphic chromosome, Proc. Natl. Acad. Sci. U. S. A., 104, 14872, 10.1073/pnas.0702356104 · DOI · Paper page
  42. Saeij, 2005, Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host, Trends Parasitol., 21, 476, 10.1016/j.pt.2005.08.001 · DOI · Paper page
  43. Su, 2012, Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages, Proc. Natl. Acad. Sci. U. S. A., 109, 5844, 10.1073/pnas.1203190109 · DOI · Paper page
  44. Shwab, 2018, Human impact on the diversity and virulence of the ubiquitous zoonotic parasite Toxoplasma gondii, Proc. Natl. Acad. Sci. U. S. A., 115, E6956, 10.1073/pnas.1722202115 · DOI
  45. Lorenzi, 2016, Local admixture of amplified and diversified secreted pathogenesis determinants shapes mosaic Toxoplasma gondii genomes, Nat. Commun., 7, 10.1038/ncomms10147 · DOI · Paper page
  46. Jensen, 2015, Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination, mBio, 6, 10.1128/mBio.02280-14 · DOI
  47. Dao, 2001, Successful reinfection of chronically infected mice by a different Toxoplasma gondii genotype, Int. J. Parasitol., 31, 63, 10.1016/S0020-7519(00)00151-X · DOI
  48. Wang, 2017, Proteomic differences between developmental stages of Toxoplasma gondii revealed by iTRAQ-based quantitative proteomics, Front. Microbiol., 8, 985, 10.3389/fmicb.2017.00985 · DOI
  49. Szabo, 2017, Toxoplasma gondii: one organism, multiple models, Trends Parasitol., 33, 113, 10.1016/j.pt.2016.11.007 · DOI
  50. Koblansky, 2013, Recognition of profilin by Toll-like receptor 12 is critical for host resistance to Toxoplasma gondii, Immunity, 38, 119, 10.1016/j.immuni.2012.09.016 · DOI · Paper page
  51. Howard, 2011, The IRG protein-based resistance mechanism in mice and its relation to virulence in Toxoplasma gondii, Curr. Opin. Microbiol., 14, 414, 10.1016/j.mib.2011.07.002 · DOI
  52. Hakimi, 2017, Toxoplasma effectors targeting host signaling and transcription, Clin. Microbiol. Rev., 30, 615, 10.1128/CMR.00005-17 · DOI · Paper page
  53. Bougdour, 2013, Host cell subversion by Toxoplasma GRA16, an exported dense granule protein that targets the host cell nucleus and alters gene expression, Cell Host Microbe, 13, 489, 10.1016/j.chom.2013.03.002 · DOI · Paper page
  54. Braun, 2013, A Toxoplasma dense granule protein, GRA24, modulates the early immune response to infection by promoting a direct and sustained host p38 MAPK activation, J. Exp. Med., 210, 2071, 10.1084/jem.20130103 · DOI · Paper page
  55. Olias, 2016, Toxoplasma effector recruits the Mi-2/NuRD complex to repress STAT1 transcription and block IFN-γ-dependent gene expression, Cell Host Microbe, 20, 72, 10.1016/j.chom.2016.06.006 · DOI · Paper page
  56. Gay, 2016, Toxoplasma gondii TgIST co-opts host chromatin repressors dampening STAT1-dependent gene regulation and IFN-γ-mediated host defenses, J. Exp. Med., 213, 1779, 10.1084/jem.20160340 · DOI · Paper page
  57. Ma, 2014, Selective and strain-specific NFAT4 activation by the Toxoplasma gondii polymorphic dense granule protein GRA6, J. Exp. Med., 211, 2013, 10.1084/jem.20131272 · DOI
  58. Rosowski, 2011, Strain-specific activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii dense granule protein, J. Exp. Med., 208, 195, 10.1084/jem.20100717 · DOI · Paper page
  59. Butcher, 2011, Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control, PLoS Pathog., 7, 10.1371/journal.ppat.1002236 · DOI · Paper page
  60. Jensen, 2011, Toxoplasma polymorphic effectors determine macrophage polarization and intestinal inflammation, Cell Host Microbe, 9, 472, 10.1016/j.chom.2011.04.015 · DOI · Paper page
  61. Etheridge, 2014, The Toxoplasma pseudokinase ROP5 forms complexes with ROP18 and ROP17 kinases that synergize to control acute virulence in mice, Cell Host Microbe, 15, 537, 10.1016/j.chom.2014.04.002 · DOI · Paper page
  62. Jeffers, 2018, A latent ability to persist: differentiation in Toxoplasma gondii, Cell. Mol. Life Sci., 75, 2355, 10.1007/s00018-018-2808-x · doi:10.1007/s00018-018-2808-x
  63. Holmes, 2017, Translational control in the latency of apicomplexan parasites, Trends Parasitol., 33, 947, 10.1016/j.pt.2017.08.006 · DOI
  64. Lesage, 2018, Cooperative binding of ApiAP2 transcription factors is crucial for the expression of virulence genes in Toxoplasma gondii, Nucleic Acids Res., 46, 6057, 10.1093/nar/gky373 · DOI
  65. Radke, 2018, Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis, PLoS Pathog., 14, 10.1371/journal.ppat.1007035 · DOI
  66. Dubey, 1999, Infection and immunity with the RH strain of Toxoplasma gondii in rats and mice, J. Parasitol., 85, 657, 10.2307/3285739 · doi:10.2307/3285739
  67. Damania, 2014, What lies within: coinfections and immunity, Cell Host Microbe, 16, 145, 10.1016/j.chom.2014.07.014 · DOI
  68. Inclan-Rico, 2018, First responders: innate immunity to helminths, Trends Parasitol., 34, 861, 10.1016/j.pt.2018.08.007 · DOI
  69. Sette, 2010, Reverse vaccinology: developing vaccines in the era of genomics, Immunity, 33, 530, 10.1016/j.immuni.2010.09.017 · DOI · Paper page
  70. Rinaudo, 2009, Vaccinology in the genome era, J. Clin. Invest., 119, 2515, 10.1172/JCI38330 · DOI · Paper page
  71. Kassegne, 2016, Immunomic approaches for antigen discovery of human parasites, Expert Rev. Proteomics, 13, 1091, 10.1080/14789450.2016.1252675 · DOI
  72. Goodswen, 2018, A gene-based positive selection detection approach to identify vaccine candidates using Toxoplasma gondii as a test case protozoan pathogen, Front. Genet., 9, 332, 10.3389/fgene.2018.00332 · DOI
  73. Gourlay, 2017, Structure and computation in immunoreagent design: from diagnostics to vaccines, Trends Biotechnol., 35, 1208, 10.1016/j.tibtech.2017.06.018 · DOI
  74. Fox, 2002, De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii, Nature, 415, 926, 10.1038/415926a · DOI · Paper page
  75. Ismael, 2006, Mic1-3 knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice, J. Infect. Dis., 194, 1176, 10.1086/507706 · DOI
  76. Fox, 2010, Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii, Infect. Immun., 78, 3744, 10.1128/IAI.00287-10 · DOI
  77. Fox, 2015, Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection, Infect. Immun., 83, 2148, 10.1128/IAI.02756-14 · DOI
  78. Lagal, 2015, AMA1-deficien Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity, Infect. Immun., 83, 2475, 10.1128/IAI.02606-14 · DOI
  79. Arroyo-Olarte, 2015, Phosphatidylthreonine and lipid-mediated control of parasite virulence, PLoS Biol., 13, 10.1371/journal.pbio.1002288 · DOI
  80. Wang, 2017, Immunization with Toxoplasma gondii GRA17 deletion mutant induces partial protection and survival in challenged mice, Front. Immunol., 8, 730, 10.3389/fimmu.2017.00730 · DOI · Paper page
  81. Wang, 2018, Live attenuated Pru:Δcdpk2 strain of Toxoplasma gondii protects against acute, chronic, and congenital toxoplasmosis, J. Infect. Dis., 218, 768, 10.1093/infdis/jiy211 · DOI
  82. Mévélec, 2010, Mic1-3 knockout Toxoplasma gondii is a good candidate for a vaccine against T. gondii-induced abortion in sheep, Vet. Res., 41, 49, 10.1051/vetres/2010021 · DOI

Cited by

See all 187

Metadata

Authors
Wang, J.-L., Zhang, N.-Z., Li, T.-T., He, J.-J., Elsheikha, H. M., & Zhu, X.-Q.
Venue
Trends in Parasitology
Publisher
Elsevier BV
Published
2019-03
Volume
35
Issue
3
Pages
239-253
ISSN
1471-4922 (ISSN-L)
OpenAlex
W2912655637
Cited by
187
References
3
FWCI
5.03
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • National Natural Science Foundation of China (31802180, 31230073)
  • National Key Research and Development Program of China (2017YFD0501304)
  • International Science and Technology Cooperation Project of Gansu Provincial Key Research and Development Program (17JR7WA031)
  • Elite Program of Chinese Academy of Agricultural Sciences, and the Agricultural Science and Technology Innovation Program (CAAS-ASTIP-2016-LVRI-03)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in the Development of Anti-Toxoplasma gondii Vaccines: Challenges, Opportunities, and Perspectives. https://app.cochat.ai/papers/10.1016/j.pt.2019.01.005
The paper
Wang, J.-L., Zhang, N.-Z., Li, T.-T., He, J.-J., Elsheikha, H. M., & Zhu, X.-Q. (2019). Advances in the Development of Anti-Toxoplasma gondii Vaccines: Challenges, Opportunities, and Perspectives. Trends in Parasitology. https://doi.org/10.1016/j.pt.2019.01.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.